Special Issue "Ten Years of iPSCs: Current Status and Future Perspectives"
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: closed (30 November 2017)
Dr. Giovanni Amabile
Chief Scientific Officer, Adienne Pharma and Biotec, Lugano, Switzerland
Interests: induced pluripotent stem cells; epigenetics; hematopoiesis; neurogenesis; early and late stage clinical trials
The landmark finding in 2006, that lineage-restricted cells could be reprogrammed to a pluripotent state, has revolutionized the regenerative medicine field, opening new therapeutic prospects for several severe conditions. Induced pluripotent Stem Cells (iPS) can be obtained by using numerous reprogramming strategies that became step-by-step safer by avoiding the use of oncogenes and the integration of transgenes.
Pluripotent stem cells hold the greatest promise given their potential to differentiate into all the cell types of the human body and their potential as treatment of several genetic or degenerative diseases.
In this Special Issue, we invite your contributions, either in the form of original research articles, reviews, or shorter “Perspective” articles on all aspects related to the theme of “Transforming Induced Pluripotent Stem Cells into Novel Therapeutic Opportunities”. Articles with mechanistic and functional insights from a cell and molecular biological perspective are especially welcome.
Dr. Giovanni Amabile
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- induced pluripotent stem cells
- regenerative medicine
- cell therapies
- clinical development
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Translational Prospects and Challenges for Human iPS Cell Research in Drug Discovery
Authors: Masaki Hosoya and Katherine Czysz
Affiliations: Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
Abstract: Despite the large efforts to secure drug research and development processes, the success at clinical stages are still challenging and the biggest issue underlying them is the gap between pre-clinical and clinical setting. Discovery of human iPS cells have great impact on drug discovery, because it enabled us to humanize a variety of pharmacological and toxicological models in vitro. Availability of human iPS cell-derived cells, especially as alternative of difficult-to-access tissues/organs, is expanding; however, there still remain the gap between pre-clinical and clinical studies. Biomarker is an essential piece of the translational effort from benchside to bedside, because it can be common metrics to assess pharmacological and toxicological effects in both setting. Most of all in vitro models for human diseases are validated with some kind of biomarkers for maturity and functionality but their applicability to clinical studies is not so much taken cared. In this review, current status of human iPS cell-derived models is reassessed from the view point of translatability and the importance of earlier consideration for clinically relevant biomarker is discussed.